Skip to Content
200 Hawkins Drive
358 Medical Research Facility
Iowa City, Iowa 52242-2600
Phone: (319) 356-4848
Research Study on Treating Influenza in Individuals with an Underlying Illness
The University of Iowa Vaccine Research and Education Unit is conducting a study on treating Influenza that will evaluate the effectiveness of Tamiflu® versus a combination antiviral medication. You are invited to participate in this study if you have influenza like symptoms that started no more than 4 days (96 hours) ago and have an illness that may be made worse by having influenza. These illnesses can include, but are not limited to: asthma, diabetes, heart diseases, HIV, COPD, and obesity. Individuals who are currently hospitalized are eligible to participate. You must be 18 or older.
Participants will be asked to complete 4 study visits that will occur in the clinic and additional 5 months of pregnancy surveillance. For women, pregnancy surveillance consists of 5 in-clinic pregnancy tests. For men, pregnancy surveillance consists of 5 phone calls.
Compensation is provided. For more information, please call (319) 356-4848, or email firstname.lastname@example.org. Also check out our Facebook page at www.facebook.com/UIowaVaccineResearch.
The purpose of this study is to evaluate safety and how your body responds to a Tuberculosis (TB) vaccine alone and with an adjuvant called GLA. An adjuvant is a substance that is added to vaccines to increase the body response to the vaccine.
Tuberculosis (TB) is an infectious disease caused by a bacterium. TB is one of the leading causes of illness and death around the world with an estimated 8 million cases of active TB each year and 1.3 million deaths annually. Current treatment requires people to take multiple antibiotics for many months (often 6 months or more), which makes it difficult for people to tolerate these medications and to finish the required length of therapy. Given the widespread occurrence of TB, the high rates of illness and death and the complexities of the treatment, effective TB vaccines could have great impacts on global health. The current licensed BCG vaccine doesn't prevent TB infections in adults and has only limited effectiveness in children, so there is a great need for a more effective vaccine. By developing a vaccine that allows you to develop antibodies to TB, we may be able to prevent or lessen TB infections.
Volunteers will be given three injections of the vaccine over the span of 2 months and we will draw their blood to see how the body responds to the vaccine. We will also follow volunteers to see how they tolerate their vaccine.
We are currently recruiting volunteers who are 18 to 49 years of age and are in good health.
To learn more, call (319) 356-4848, or email email@example.com.
The purpose of this study is to evaluate the safety of how the body metabolizes a medication called oxfendazole. The medication is being tested to see if it can be used to treat humans with neurocysticercosis, which is a disease caused by a parasite that can enter the brain and cause seizures and other problems. Approximately 50,000 people worldwide die each year because of this parasite, and it is estimated that 1000 cases occur annually in the United State. The current treatment requires multiple doses of medication over the course of several weeks and a complete cure is only successful in 50% of the cases. Studies in pigs show that oxfendazole is able to kill this parasite with a single dose of medication. These data suggest that oxfendazole has the potential to be useful since a single oral dose might be a way to treat neurocysticercosis in humans.
We are currently recruiting volunteers who are 18 to 45 years of age and are in good health. If you are a woman who is able to have children, you will not be able to participate.
This study will be the first test of oxfendazole in humans. Subjects will be given a single dose of the drug and we will test blood and urine to see how much of the drug gets into the blood stream and how long it lasts in the body. We will also follow subjects to see how they tolerate the medication. Some people in this study will get a placebo and some people will get oxfendazole.
To learn more, call 319-356-4848 or e-mail firstname.lastname@example.org.
Interested in hearing about our latest studies? Sign up to be a part of our registry. As a member of our registry, we will notify you of any studies we are doing that you may be eligible to participate in.
Simply complete this online registration form to become a member.
Copyright © 2015 The University of Iowa. All Rights Reserved.